Item

Camidanlumab Tesirine for Relapsed or Refractory Classic Hodgkin Lymphoma: A Phase 2 Study

Herrera, A. F.
; 
Ansell, S. M.
; 
Zinzani, P. L.
; 
Radford, J.
; 
Maddocks, K. J.
; 
Pinto, A.
; 
Collins, G. P.
; 
Bachanova, V.
; 
Bartlett, N. L.
; 
Bence-Bruckler, I.
... show 10 more
Citations
Google Scholar:
Lookup
Altmetric:
Abstract
Outcomes in classic Hodgkin lymphoma (cHL) have steadily improved; however, additional therapies are needed for patients who relapse or do not respond to novel agents. Here, we report the efficacy and safety of camidanlumab tesirine (Cami), an anti-CD25 antibody-drug conjugate, in patients with relapsed/refractory cHL following brentuximab vedotin/programmed cell death protein 1 inhibitor therapies from the phase 2 ADCT-301-201 study. Eligible patients were adults with cHL who had received ≥3 prior lines of systemic therapy (or ≥2 if ineligible for hematopoietic stem cell transplant). Patients received 45 μg/kg Cami (intravenously, once every 3 weeks [Q3W]) in cycles 1 to 2, followed by 30 μg/kg IV Q3W for ≤1 year. The primary endpoint was overall response rate (ORR) per 2014 Lugano Classification. Secondary endpoints included complete response rate (CRR), progression-free survival (PFS), and overall survival (OS). In total, 117 patients were enrolled with a median age of 37.0 (range, 19, 87) years. The ORR was 70.1% (95% CI, 60.9, 78.2) with a CRR of 33.3% (24.9, 42.6). The median PFS was 9.13 (95% CI, 5.3, 15.0) months; median OS was not reached. Thirty-three (28.2%) patients discontinued treatment because of treatment-emergent adverse events; the most common reasons were skin and subcutaneous tissue disorders (10 [8.5%] patients), infections and infestations (5 [4.3%]), and nervous systems disorders (5 [4.3%]). Guillain-Barré- or polyradiculopathy-type events occurred in 8 (6.8%) patients. Cami was efficacious in this heavily pretreated population; however, the efficacy was overshadowed by substantial issues with the safety profile. NCT04052997.
Authors
Herrera, A. F.
Ansell, S. M.
Zinzani, P. L.
Radford, J.
Maddocks, K. J.
Pinto, A.
Collins, G. P.
Bachanova, V.
Bartlett, N. L.
Bence-Bruckler, I.
Hamadani, M.
Kline, J.
Mayer, J.
Savage, K. J.
Advani, R. H.
Caimi, P. F.
Casasnovas, O.
Feldman, T. A.
Hess, B. T.
Bastos-Oreiro, M.
Iyengar, S.
Szomor, Á.
Townsend, W.
André, M.
Dyczkowski, J.
Havenith, K.
Toukam, M.
Pantano, S.
Cruz, H. G.
Wang, L.
Negievich, Y.
Lucero, M.
Wuerthner, J. U.
Carlo-Stella, C.
Affiliation
City of Hope, Duarte, California, United States. Mayo Clinic, Rochester, Minnesota, United States. Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. University of Manchester and the Christie NHS Foundation Trust, Manchester, United Kingdom. The Ohio State University, Columbus, Ohio, United States. National Cancer Institute, IRCCS-Fondazione 'G. Pascale', Naples, Italy. Oxford University Hospitals, Oxford, United Kingdom. University of Minnesota, Minneapolis, Minnesota, United States. Washington University School of Medicine, St. Louis, Missouri, United States. Ottawa Hospital Research Institute, Ottawa, Canada. Medical College of Wisconsin, Wauwatosa, Wisconsin, United States. University of Chicago, Chicago, Illinois, United States. University Hospital Brno, Brno, Czech Republic. BC Cancer, Centre for Lymphoid Cancer, Vancouver, Canada. Stanford University, Stanford, California, United States. Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States. C.H.U Dijon Bourgogne, Dijon, France. Hackensack University Medical Center, Hackensack, New Jersey, United States. The Medical University of South Carolina, Charleston, South Carolina, United States. Hospital General Universitario Gregorio Marañon, Madrid, Spain. Royal Marsden Hospital and Institute of Cancer Research, Sutton, United Kingdom. University of Pécs, Pecs, Hungary. NIHR Clinical Research Facility, University College Hospitals London, London, United Kingdom. CHU UCL Namur, Yvoir, Belgium. ADC Therapeutics SA, Épalinges, Switzerland. ADC Therapeutics, London, United Kingdom. ADC Therapeutics America, New Providence, New Jersey, United States. ADC Therapeutics SA, Épalinges, Switzerland, Epalinges, Switzerland. ADC Therapeutics SA, Epalinges, Switzerland. ADC Therapeutics Inc, Murray Hill, New Jersey, United States. ADC Therapeutics, New Providence, New Jersey, United States. FoRx Therapeutics, Basel, Switzerland. Humanitas University, Pieve Emanuele, Italy.
Description
Date
2025
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Article
Citation
Herrera AF, Ansell SM, Zinzani PL, Radford J, Maddocks KJ, Pinto A, et al. Camidanlumab Tesirine for Relapsed or Refractory Classic Hodgkin Lymphoma: A Phase 2 Study. Blood advances. 2025 Aug 14. PubMed PMID: 40811783. Epub 2025/08/14 22:52. eng.
Journal Title
Journal ISSN
Volume Title
URI
https://christie.openrepository.com/handle/10541/627565
Embedded videos